Oral macrocyclic PCSK9-inhibiting peptide · Fact sheet
Enlicitide
Also known as Enlicitide decanoate · MK-0616 · Lipfendra
Enlicitide is the oral peptide in Lipfendra, approved to lower LDL cholesterol in adults with hypercholesterolemia. Its trials support cholesterol reduction; direct cardiovascular event prevention with enlicitide is a separate question.
What is Enlicitide?
Enlicitide inhibits PCSK9, helping preserve LDL receptors that remove cholesterol from blood. Its macrocyclic peptide structure differs from injectable antibody PCSK9 medicines.
Benefits & claims
Interest centers on LDL reduction and an oral approach to PCSK9 inhibition. Lower cholesterol and fewer cardiovascular events are related but distinct study endpoints.
What the evidence supports
- The controlled trials support substantial LDL lowering in the studied adult populations.
- Outcome evidence for other lipid medicines should not be presented as a completed enlicitide cardiovascular-outcomes trial.
Research areas
- LDL cholesterol
- Heterozygous familial hypercholesterolemia
- PCSK9 inhibition
Dosage & frequency
Product-specific label informationLipfendra is an oral PCSK9-directed medicine with a labeled adult cholesterol regimen. Its fasting requirement is part of the product-specific evidence.
Lipfendra
Adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia
- Amount
- 20 mg
- Frequency
- Once daily
- Route studied or labeled
- Oral
Morning fasting administration; label specifies waiting at least 30 minutes before food.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Earliest labeled response assessment
- LDL-C response may be assessed as early as four weeks.
Formulation differences
- Lipfendra tablets are distinct from injectable PCSK9 antibodies.
Interactions & precautions
- The label reports no clinically meaningful interactions in the evaluated studies, including selected common oral medicines; that is not a guarantee for every combination.
What is still unresolved
- The label does not establish an anti-aging indication.
Side effects & risks
- Overall adverse-reaction frequency was similar to placebo in the broad hypercholesterolemia trial.
- Diarrhea and dizziness occurred more often in the familial-hypercholesterolemia trial.
- Pregnancy and breastfeeding involve specific uncertainties and precautions in the label.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesThe label summarizes two 52-week randomized trials, including a large hypercholesterolemia study and a heterozygous familial hypercholesterolemia study. The approved endpoint is LDL reduction.
Studies
Completed Phase 3 Merck-sponsored trial with LDL and safety outcomes; results posted.
Completed Phase 3 trial in heterozygous familial hypercholesterolemia; results posted.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
FDA approved Lipfendra on July 15, 2026, as an adjunct to diet and exercise to lower LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Approved uses
- Lipfendra: LDL reduction in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia
Lipfendra FDA approved in 2026
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Direct cardiovascular-event outcomes with enlicitide
- Long-term experience beyond the pivotal studies
- Uncommon adverse effects in broader use
Summary
Enlicitide is an approved oral peptide with LDL-lowering evidence, not proof that every downstream cardiovascular claim is already established.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: Lipfendra prescribing information
Product-specific approval, LDL results, and adverse effects.
- clinical trialsCORALreef Lipids registry
Completed Phase 3 Merck-sponsored trial with LDL and safety outcomes; results posted.
- clinical trialsCORALreef HeFH registry
Completed Phase 3 trial in heterozygous familial hypercholesterolemia; results posted.